Lurbinectedin–Checkpoint Inhibitor Combinations for Solid Tumor Immune Evasion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for more effective cancer therapies, particularly for solid tumors, as existing immune checkpoint inhibitor (ICI) therapies may not fully address the immune evasion strategies employed by certain cancers.

Innovation Solution

Combining lurbinectedin, a selective inhibitor of oncogenic transcription, with immune checkpoint inhibitors such as antibodies targeting CTLA-4, PD-1, or PD-L1, to enhance immune response against solid tumors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint inhibitor therapy is used alone, then immune response is stimulated, but tumor progression continues due to immune evasion mechanisms

Engineering Contradiction:

Improveefficacy of immune responseVSAvoidtumor growth control

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent combines lurbinectedin (a transcriptional inhibitor) with immune checkpoint inhibitors (ICIs) to create a synergistic therapy. Lurbinectedin inhibits oncogenic transcription and induces immunogenic cell death, while ICIs block immune checkpoints (PD-1/PD-L1, CTLA-4). This combination merges two mechanisms of action to overcome tumor immune evasion and enhance antitumor immunity, resolving the contradiction by adding a transcriptional inhibition component to the immune stimulation approach.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The therapy uses a composite approach combining a small molecule transcriptional inhibitor (lurbinectedin) with monoclonal antibodies (ICIs). This composite therapy targets multiple pathways simultaneously: transcriptional regulation, immune checkpoint blockade, and immunogenic cell death, thereby achieving both reliable immune response and effective tumor growth control.

Inventive Principle:

Principle #40Composite materials

2Reliability

If lurbinectedin is combined with immune checkpoint inhibitors, then antitumor immunity is enhanced, but treatment complexity increases

Engineering Contradiction:

Improveantitumor immune responseVSAvoidcombination therapy regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

Lurbinectedin acts as an intermediary that bridges the gap between chemotherapy and immunotherapy. It induces immunogenic cell death and modulates the tumor microenvironment, thereby enhancing the efficacy of immune checkpoint inhibitors. This intermediary mechanism allows the combination therapy to achieve synergistic effects while managing the complexity through a clear mechanistic rationale.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If standard chemotherapy is used, then tumor cells are killed, but immune response is not adequately stimulated

Engineering Contradiction:

Improvetumor cell killingVSAvoidimmune response stimulation

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent converts the harmful effect of conventional chemotherapy (non-immunogenic cell death) into a beneficial immune-stimulating effect through lurbinectedin. Lurbinectedin specifically induces immunogenic cell death, which releases danger signals and activates the immune system. This transforms the traditional chemotherapy paradigm into an immunotherapeutic approach, simultaneously achieving tumor cell killing and immune response stimulation.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250295656A1Combination of lurbinectedin and immune checkpoint inhibitors

Publication Date: 2025.09.25 PHARMA MAR SA

AI summary

Described are combination therapies for the treatment of solid tumours, said therapies comprising lurbinectedin and an immune checkpoint inhibitor, for example, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies.